Loading stock data…
$2.49+0.03 (+1.21%)
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.
Matinas BioPharma Holdings, Inc. in the Healthcare sector is trading at $2.49 with a market capitalization of $2M. The stock is currently near its 52-week low of $2.27, remaining 236.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.55M↑ | -$1.94M↓ | -$1.60M↓ | -$1.58M↑ | -$1.84M |
| Net Income | -$1.33M↑ | -$1.92M↓ | -$1.91M↓ | -$1.53M↑ | -$5.25M |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocry...